Stem definition | Drug id | CAS RN |
---|---|---|
1732 | 537-46-2 |
Dose | Unit | Route |
---|---|---|
15 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 0 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 1000 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 40 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.92 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 67 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 4.30 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 4.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.85 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 12 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 31, 1943 | FDA | RECORDATI RARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug abuse | 2994.92 | 49.07 | 698 | 2534 | 64828 | 53281006 |
Toxicity to various agents | 1059.33 | 49.07 | 417 | 2815 | 219181 | 53126653 |
Completed suicide | 426.35 | 49.07 | 193 | 3039 | 138008 | 53207826 |
Cardio-respiratory arrest | 202.19 | 49.07 | 89 | 3143 | 58669 | 53287165 |
Death | 197.14 | 49.07 | 166 | 3066 | 357066 | 52988768 |
Respiratory arrest | 184.09 | 49.07 | 71 | 3161 | 33469 | 53312365 |
Cardiac arrest | 168.33 | 49.07 | 91 | 3141 | 93576 | 53252258 |
Intentional product misuse | 102.72 | 49.07 | 53 | 3179 | 49339 | 53296495 |
Poisoning | 78.27 | 49.07 | 30 | 3202 | 13820 | 53332014 |
Substance abuse | 70.60 | 49.07 | 21 | 3211 | 4473 | 53341361 |
Drug screen positive | 64.78 | 49.07 | 19 | 3213 | 3853 | 53341981 |
Overdose | 52.57 | 49.07 | 47 | 3185 | 107689 | 53238145 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug abuse | 3758.03 | 50.78 | 1066 | 4201 | 79177 | 32429082 |
Toxicity to various agents | 1573.11 | 50.78 | 690 | 4577 | 177351 | 32330908 |
Completed suicide | 323.44 | 50.78 | 195 | 5072 | 92322 | 32415937 |
Respiratory arrest | 288.31 | 50.78 | 124 | 5143 | 28784 | 32479475 |
Cardio-respiratory arrest | 253.85 | 50.78 | 140 | 5127 | 55849 | 32452410 |
Cardiac arrest | 194.84 | 50.78 | 145 | 5122 | 96631 | 32411628 |
Drug abuser | 144.67 | 50.78 | 45 | 5222 | 4139 | 32504120 |
Overdose | 130.91 | 50.78 | 110 | 5157 | 86967 | 32421292 |
Intentional product misuse | 107.61 | 50.78 | 69 | 5198 | 35982 | 32472277 |
Death | 106.68 | 50.78 | 207 | 5060 | 382310 | 32125949 |
Poisoning | 104.88 | 50.78 | 46 | 5221 | 11112 | 32497147 |
Incorrect route of product administration | 83.93 | 50.78 | 40 | 5227 | 11686 | 32496573 |
Accidental overdose | 83.60 | 50.78 | 47 | 5220 | 19292 | 32488967 |
Drug screen positive | 76.57 | 50.78 | 28 | 5239 | 4213 | 32504046 |
Substance abuse | 69.04 | 50.78 | 30 | 5237 | 7077 | 32501182 |
Brain oedema | 60.10 | 50.78 | 33 | 5234 | 12927 | 32495332 |
Amphetamines positive | 54.87 | 50.78 | 11 | 5256 | 160 | 32508099 |
Source | Code | Description |
---|---|---|
ATC | N06BA03 | NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics |
FDA CS | M0001015 | Amphetamines |
FDA PE | N0000175372 | Appetite Suppression |
FDA EPC | N0000175425 | Amphetamine Anorectic |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D018759 | Adrenergic Uptake Inhibitors |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D000697 | Central Nervous System Stimulants |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018765 | Dopamine Uptake Inhibitors |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D013566 | Sympathomimetics |
CHEBI has role | CHEBI:35337 | analeptic drug |
CHEBI has role | CHEBI:35471 | psychopharmaceuticals |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:50910 | agente neurotoxico |
CHEBI has role | CHEBI:78298 | environmental contaminants |
FDA PE | N0000175651 | Increased Sympathetic Activity |
FDA PE | N0000175729 | Central Nervous System Stimulation |
FDA EPC | N0000175739 | Central Nervous System Stimulant |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Attention deficit hyperactivity disorder | indication | 406506008 | |
Obesity | indication | 414916001 | DOID:9970 |
Gilles de la Tourette's syndrome | contraindication | 5158005 | DOID:11119 |
Suicidal thoughts | contraindication | 6471006 | |
Dependent drug abuse | contraindication | 6525002 | |
Alcoholism | contraindication | 7200002 | |
Hyperammonemia | contraindication | 9360008 | |
Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
Bipolar disorder | contraindication | 13746004 | DOID:3312 |
Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Feeling agitated | contraindication | 24199005 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Depressive disorder | contraindication | 35489007 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Hyperactive behavior | contraindication | 44548000 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic heart failure | contraindication | 48447003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Anorexia nervosa | contraindication | 56882008 | DOID:8689 |
Hepatic failure | contraindication | 59927004 | |
Aggressive behavior | contraindication | 61372001 | |
Substance abuse | contraindication | 66214007 | |
Psychotic disorder | contraindication | 69322001 | |
Arteriosclerotic vascular disease | contraindication | 72092001 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Sleep apnea | contraindication | 73430006 | DOID:0050847 |
Cardiomyopathy | contraindication | 85898001 | DOID:0050700 |
Weight loss | contraindication | 89362005 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Structural disorder of heart | contraindication | 128599005 | |
Seizure disorder | contraindication | 128613002 | |
Motor tic disorder | contraindication | 230337001 | |
Cerebrovascular accident | contraindication | 230690007 | |
Mania | contraindication | 231494001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Sleep automatism | contraindication | 247962006 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Cardiovascular event risk | contraindication | 395112001 | |
Visual impairment | contraindication | 397540003 | |
Respiratory insufficiency | contraindication | 409623005 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Porphyria | contraindication | 418470004 | |
Hypertensive urgency | contraindication | 443482000 | |
Acute exacerbation of asthma | contraindication | 708038006 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.73 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium-dependent dopamine transporter | Transporter | INHIBITOR | Ki | 7.61 | PDSP | CHEMBL | |||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.38 | PDSP | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 5.08 | CHEMBL | |||||
Sodium-dependent serotonin transporter | Transporter | INHIBITOR | Ki | 6.13 | PDSP | ||||
Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | Ki | 7.91 | PDSP | ||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5 | PDSP | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 6.13 | PDSP | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 6.09 | PDSP | |||||
Trace amine-associated receptor 1 | GPCR | AGONIST | EC50 | 5.89 | CHEMBL | ||||
Trace amine-associated receptor 1 | GPCR | EC50 | 6.88 | CHEMBL | |||||
Trace amine-associated receptor 1 | GPCR | EC50 | 7.15 | CHEMBL | |||||
Trace amine-associated receptor 1 | GPCR | EC50 | 5.28 | CHEMBL | |||||
Synaptic vesicular amine transporter | Transporter | Ki | 5.61 | CHEMBL |
ID | Source |
---|---|
4019821 | VUID |
N0000147910 | NUI |
D02242 | KEGG_DRUG |
51-57-0 | SECONDARY_CAS_RN |
4018483 | VANDF |
4019821 | VANDF |
C0025611 | UMLSCUI |
CHEBI:6809 | CHEBI |
B40 | PDB_CHEM_ID |
CHEMBL1201201 | ChEMBL_ID |
DB01577 | DRUGBANK_ID |
CHEMBL1200952 | ChEMBL_ID |
D008694 | MESH_DESCRIPTOR_UI |
10836 | PUBCHEM_CID |
1879 | INN_ID |
4803 | IUPHAR_LIGAND_ID |
44RAL3456C | UNII |
6816 | RXNORM |
1988 | MMSL |
5066 | MMSL |
d00805 | MMSL |
001797 | NDDF |
004722 | NDDF |
387329009 | SNOMEDCT_US |
387499002 | SNOMEDCT_US |
8692006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Methamphetamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0389 | TABLET | 5 mg | ORAL | ANDA | 25 sections |
Desoxyn | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55292-102 | TABLET | 5 mg | ORAL | NDA | 25 sections |
Desoxyn | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55292-104 | TABLET | 5 mg | ORAL | NDA | 25 sections |
Methamphetamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68308-115 | TABLET | 5 mg | ORAL | ANDA | 29 sections |